Method for analyzing dependent heparin platelet activation
Patent Information
- Application Number
- EP2023702439
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-28
- Filing Date
- 2023-01-27
- Publication Date
- 2024-12-04
AI Technical Summary
Current functional tests for diagnosing heparin-induced thrombocytopenia require fresh platelets from healthy donors, are prone to variability, and lack standardization, making them inefficient and challenging to perform, especially in hemostasis laboratories where rapid and reliable results are needed.
A method using whole blood from patients, diluted in a buffer, with exogenous platelet factor 4 and monoclonal antibodies, to analyze heparin-dependent platelet activation through specific labeling and flow cytometry, eliminating the need for healthy donor platelets and standardizing the results.
This method provides a sensitive and specific diagnosis of heparin-induced thrombocytopenia, reducing variability and turnaround time, while ensuring accurate evaluation of patient-specific platelet activation without relying on healthy donor platelets.
Smart Images

Figure IMGF000009_0001 
Figure IMGF000009_0002 
Figure IMGF000013_0001
Abstract
Description
[0001] DESCRIPTION
[0002] Method for analyzing heparin-dependent platelet activation
[0003] The present invention relates to a method for analyzing platelet activation induced by antibodies directed against polyanion-modified platelet factor 4 (FP4), preferably directed against the FP4 / heparin complex, as well as to a method for in vitro diagnosis of heparin-induced thrombocytopenia or exclusion diagnosis of heparin-induced thrombocytopenia in a patient, comprising specific steps.
[0004] Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy. It is the consequence of an atypical immune response characterized by the synthesis of IgG antibodies specifically directed against polyanion-modified platelet factor 4 (PF4), e.g., heparin (H). These anti-PF4 polyanion-modified antibodies activate platelets via the FcγRIlA receptor.
[0005] Heparin is widely used in hemodialysis, cardiac surgery, particularly with cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO) procedures, and intensive care. In routine practice, HIT is frequently suspected in hospitalized patients treated with heparin, but this diagnosis is confirmed in only approximately 1 to 3% of patients receiving unfractionated heparin (UFH) therapy, and more rarely in those treated with low molecular weight heparin (LMWH).
[0006] It is important to note that some patients treated with heparin develop polyanion-modified anti-FP4 antibodies that do not induce platelet activation. They are not pathogenic and therefore do not cause HIT. This is particularly the case during ECMO or CPB procedures, where nearly 50% of patients develop polyanion-modified anti-FP4 antibodies, but these antibodies are only capable of activating platelets in 2 to 3% of cases.
[0007] HIT is in fact considered a clinical-biological syndrome, the complete diagnosis of which is based on:
[0008] 1. the appearance of one or more clinical events associated with HIT (thrombocytopenia, thrombosis, etc.), and 2. the detection, in the patient's plasma or serum, of anti-FP4 antibodies modified by a polyanion capable of activating platelets in vitro in the presence of heparin.
[0009] Two types of tests are thus used for the biological diagnosis of TlH:
[0010] - immunological tests, which detect the presence of polyanion-modified anti-FP4 antibodies, regardless of their ability to activate cells; and
[0011] - functional tests, which highlight heparin-dependent activation of platelets by these antibodies. In practice, platelet activation is demonstrated in the presence of therapeutic concentrations of heparin (i.e. between 0.1 and 1 IU / ml of heparin), whereas it is completely inhibited by a high concentration of heparin (i.e. between 10 and 100 IU / ml).
[0012] The main advantage of immunological tests is their high sensitivity (with an excellent negative predictive value), explaining why a negative result allows in a large majority of cases to exclude the disease. However, due to their insufficient positive predictive value, a positive result must, in the large majority of cases, be associated with a functional test to confirm or not the pathogenic nature of the antibodies and therefore the diagnosis of HIT. The combination of these two types of tests is necessary to confirm HIT, or at least to considerably improve the specificity of the biological diagnosis.
[0013] To date, all available functional tests require fresh platelets or blood from healthy donors. The effect of patient plasma or serum on platelet activation is studied in the presence of heparin. Some tests also add exogenous FP4 to enhance the detection of platelet activation induced by pathogenic antibodies.
[0014] The most powerful tests are the radiolabeled serotonin release assay (SRA) and the heparin-induced platelet aggregation assay (HIPA), both performed with fresh washed platelets obtained from one or more healthy donors. The sensitivity and specificity of SRA and HIPA are greater than 95%. Other functional tests that also use platelets from healthy subjects are also available but have lower performance. To date, two commercial tests use the flow cytometry technique: Emo-test HIT Confirm® (5- Diagnostics, Basel, Switzerland) and HITAIertTM KIT (IQ Products, DL Groningen, the Netherlands).The performance of currently available functional tests is variable, with heterogeneity of results due to the use of different methodologies, variability of washed platelets from healthy donors, but also different positivity criteria to confirm HIT.
[0015] Furthermore, numerous studies have highlighted variable reactivity of platelets to HIT antibodies, which implies that it is often necessary to carry out these tests with platelets from several healthy subjects before reliably concluding a negative result for a patient.
[0016] The use of platelets from healthy subjects in fact involves several pitfalls:
[0017] - the prior consent of healthy subjects must be obtained before sampling;
[0018] - the great difficulty of accessing healthy donors;
[0019] - donor selection, due to a large variability in platelet response from one subject to another; and
[0020] - the washing step which can have an impact on the activity of the packets.
[0021] Finally, the vast majority of tests available today are performed after a platelet isolation step. However, HIT results from multicellular activation induced by pathogenic anti-FP4 / H antibodies. Thus, monocytes and neutrophils are also stimulated by these antibodies and can potentiate platelet activation. Currently, only one functional test for the diagnosis of HIT is performed on whole blood (HIMEA: Heparin-Induced Multiple Electrode Aggregometry), but it also requires a sample from a healthy subject.
[0022] There is therefore a very strong need, particularly from hemostasis laboratories, for a sensitive and specific functional test, which does not require the collection of healthy donors and which also does not require a platelet isolation step.
[0023] The lack of standardization of functional tests for diagnosing HIT is also a major pitfall. Hemostasis laboratories need a functional test with standardized interpretation of results and a relatively short turnaround time (such as less than 24 to 48 hours excluding weekends).
[0024] The present invention makes it possible to meet these expectations.
[0025] The present invention thus relates to a method for analyzing platelet activation in a patient suspected of having thrombocytopenia induced by anti-FP4 antibodies modified by a polyanion, in particular antibodies directed against the FP4 factor modified by heparin.
[0026] The present invention also relates to a method for in vitro diagnosis of TlH or for confirming the diagnosis of TlH in a patient suspected of having TlH.
[0027] It also relates to a method for in vitro diagnosis of exclusion of Tl H in a patient suspected of having Tl H.
[0028] According to its first embodiment, the subject of the present invention is a method for analyzing heparin-dependent platelet activation in a patient suspected of having thrombocytopenia induced by anti-FP4 antibodies modified by a polyanion, in particular antibodies directed against the FP4 factor modified by heparin, comprising the following steps:
[0029] 1) the preparation of a series of tests necessary for validation and standardization, hereinafter referred to as the Validation / Standardization (VS) series, said Validation / Standardization series comprising:
[0030] - mixing a sample of whole blood from said patient, diluted in an acceptable buffer, in the presence of exogenous platelet factor 4 (PF4), and a monoclonal antibody directed specifically against platelet factor 4 modified by a polyanion, preferably by heparin, or one of its fragments in order to obtain a mixture 1a;
[0031] - at least one mixture of a whole blood sample from said patient, diluted in an acceptable buffer, with exogenous FP4, a monoclonal antibody directed specifically against FP4 modified by a polyanion, or one of its fragments, and heparin in a concentration of between 0.01 and 1 μl / ml, in order to obtain at least one mixture 1b;
[0032] - at least one mixture of a whole blood sample from said patient, diluted in an acceptable buffer, with exogenous FP4, a monoclonal antibody directed specifically against FP4 modified by a polyanion, or one of its fragments, and heparin in a concentration of between 10 and 200 IU / ml, in order to obtain at least one mixture 1c;
[0033] 2) the preparation of a Patient Test (PT) series, said Patient Test series comprising:
[0034] - mixing a sample of whole blood from said patient, diluted in an acceptable buffer, with a platelet activator or a strong agonist, in order to obtain an Ago mixture;
[0035] - mixing a sample of whole blood from said patient, diluted in an acceptable buffer, to obtain the Basal mixture; - mixing a sample of whole blood from said patient, diluted in an acceptable buffer, with FP4, to obtain a mixture 2a;
[0036] - at least one mixture of a sample of whole blood from said patient, diluted in an acceptable buffer, with FP4 and heparin in a concentration equal to that used for mixture 1 b, in order to obtain a mixture 2b;
[0037] - at least one mixture of a whole blood sample from said patient, diluted in an acceptable buffer, with FP4 and heparin in a concentration equal to that used for mixture 1c, in order to obtain a mixture 2c;
[0038] 3) incubation of all mixtures of the VS and TP series then labeling of the platelet population and specific labeling of the activated platelets in this population in each mixture; and
[0039] 4) analysis of all mixtures obtained in step 3).
[0040] The method according to the invention is an in vitro method.
[0041] Preferably step 4) of analyzing all the mixtures obtained in step 3) includes measuring the specific labeling intensity of activated platelets in the platelet population of each mixture of the VS series (1a to 1c) and the TP series (Ago, Basal, and 2a to 2c).
[0042] Preferably, the method of the invention is a flow cytometry analysis method.
[0043] Preferably, the method of the invention comprises steps 1) to 4) set out above, as well as the following additional step 5), following step 4):
[0044] 5) validation of the VS series.
[0045] According to the invention, the VS series is considered to be validated if we observe:
[0046] - activation of platelets in the sample of this series induced by an antibody or antibody fragment directed specifically against FP4 modified by a polyanion, in the absence of heparin and / or in the presence of low concentrations of heparin, and
[0047] - an inhibition of this activation in the presence of high concentrations of heparin. Preferably, step 5) consists of the validation of the VS series by calculating the activation ratio of this series and the calculation of the inhibition ratio of this same series.
[0048] For the purposes of the present invention, the term "heparin-dependent platelet activation" means platelet activation induced by anti-FP4 antibodies (or antibody fragments) modified by a polyanion, or antibodies (or antibody fragments) mimicking anti-FP4 antibodies modified by a polyanion, which is observed in the absence of heparin and / or in the presence of low concentrations of heparin, and which is inhibited in the presence of high concentrations of heparin.
[0049] By "low heparin concentration" we mean a concentration typically between 0.01 and 1 μl / ml.
[0050] By "high heparin concentration" we mean a concentration typically between 10 and 200 IU / ml.
[0051] Following step 5), the method of the invention preferably comprises a step 5') of calculating the antibody-dependent platelet activation rate (called APA) of the mixtures Ago, 2a, 2b and 2c of the TP series.
[0052] Advantageously, the method of the invention is implemented for the exclusion diagnosis of HIT, or the confirmation of a diagnosis of HIT in a patient suspected of having the disease.
[0053] In this case, the method of the invention comprises steps 1) to 5') set out above, as well as a step of interpreting the results obtained on the TP series to establish a diagnosis of HIT or an exclusion of HIT.
[0054] According to a particular embodiment of this application, the method of the invention comprises steps 1) to 5') set out above, as well as a step 6), in which step 6) is as follows:
[0055] 6) the interpretation (preferably the comparison) of the antibody-dependent platelet activation (APA) levels calculated in each mixture of the TP series for the establishment of a diagnosis of HIT or an exclusion of HIT. The method according to the invention, its steps and its operating conditions, will now be detailed according to the indications below.
[0056] The method according to the invention uses whole blood samples from a patient. "Whole blood" means a blood sample comprising plasma and its formed elements (red blood cells, white blood cells and platelets and derived microparticles).
[0057] The use of whole blood from the patient eliminates the variability in the response to HIT antibodies in platelets from healthy donors. Thus, the actual activating nature of the patient's antibodies is directly assessed on their own platelets.
[0058] Furthermore, the use of whole blood from the patient allows us to benefit from the multicellular cooperation often involved during HIT.
[0059] Ultimately, the consequences of heparin-dependent, multicellular activation induced by anti-FP4 antibodies modified by a patient's polyanion on their own platelets are evaluated.
[0060] Preferably, each sample is obtained from blood samples collected in the presence of a compound that prevents blood from clotting. The compound generally used is sodium citrate, but other compounds such as hirudin or citric acid-trisodium citrate-glucose (CDA) can also be used for this purpose. Such compounds have long been known in the state of the art for the study of platelet functions.
[0061] Preferably, the total volume of the patient's whole blood sample is between 500 pL and 2 ml.
[0062] The whole blood sample can be diluted in any physiologically acceptable buffer. Preferably, physiological saline (i.e. aqueous NaCl 9 g / l solution) is used, but other buffers such as, for example, PBS buffer with different compositions (e.g., NaN310X or Citrate NaN310X) can also be used for dilution of the blood sample.
[0063] All patient whole blood samples used in the method according to the invention are used undiluted or diluted up to 1 / 10, preferably diluted in the proportion 1 / 2 to 1 / 10 ème , and preferably a quarter, in physiological serum. Such a dilution allows the use of thrombopenic blood (i.e. in which the quantity of platelets is less than 150 Giga / L).
[0064] Typically, all the mixtures of steps 1) and 2) (VS and TP series) of the method of the invention are carried out with the same buffer. from the Validation / Standardization series
[0065] The VS series includes at least 3 blends:
[0066] - mixture 1a, which corresponds to the mixture of a sample of whole blood from said patient, diluted in an acceptable buffer, with exogenous FP4 and a monoclonal antibody directed specifically against FP4 modified by a polyanion, or one of its fragments;
[0067] - at least one mixture 1b, which corresponds to the mixture of a sample of whole blood from said patient, diluted in an acceptable buffer, with exogenous FP4, a monoclonal antibody directed specifically against FP4 modified by a polyanion, or one of its fragments, and heparin in a concentration of between 0.01 and 1 IU / rnl; and
[0068] - mixture 1c, which corresponds to the mixture of a sample of whole blood from said patient, diluted in an acceptable buffer, with exogenous FP4, a monoclonal antibody directed specifically against FP4 modified by a polyanion, or one of its fragments, and heparin in a concentration of between 10 and 200 IU / rnl.
[0069] Preferably, each of the mixtures 1 a to 1 c has a volume of between 20 and 200 μl.
[0070] In practice, the aforementioned antibody perfectly mimics the effects of T1 H antibodies developed by patients. It is used as an internal positive quality control and thus allows the technical validation of the test, as well as a standardized expression of the results, which contributes to the innovative nature of the invention.
[0071] Preferably, the preparation of the VS series includes the preparation of at least 4 mixtures:
[0072] - mixing a whole blood sample from said patient, diluted in an acceptable buffer, with exogenous FP4 and a monoclonal antibody directed specifically against polyanion-modified FP4, or one of its fragments, to obtain mixture 1a;
[0073] - at least two mixtures of whole blood samples from said patient, diluted in an acceptable buffer, with exogenous FP4, a monoclonal antibody directed specifically against FP4 modified by a polyanion, or one of its fragments, and heparin in a concentration of between 0.01 and 1 IU / rnl, the concentration of heparin being different for each mixture, in order to obtain at least two mixtures 1 b; and
[0074] - mixing a whole blood sample from said patient, diluted in an acceptable buffer, with exogenous FP4, a monoclonal antibody directed specifically against FP4 modified by a polyanion, or one of its fragments, and heparin in a concentration of between 10 and 200 IU / ml, in order to obtain a mixture 1c.
[0075] Preferably, two mixtures 1 b (i.e. mixtures 1b' and 1b”) are carried out on the one hand with a heparin concentration of between 0.01 and 0.1 IU / ml for the first mixture 1b', and on the other hand between 0.2 and 1 IU / ml for the second mixture 1 b”. More preferably, the two mixtures 1 b are carried out with a heparin concentration of between 0.02 and 0.08 IU / ml, preferably approximately 0.05 IU / ml, for the first mixture 1 b'; and on the other hand with a heparin concentration of between 0.3 and 0.8 IU / ml, preferably approximately 0.5 IU / ml, for the second mixture 1 b”.
[0076] Mixture 1 c is obtained more preferably with a heparin concentration of between 50 and 150 IU / ml, preferably between 80 and 120 IU / ml, preferably approximately 100 IU / ml.
[0077] Mixtures 1b (1 b' and 1 b”) mimic the effects of low heparin concentrations, while mixture 1c mimics the effects of high heparin concentration.
[0078] Monoclonal antibody specifically directed against polyanion-modified FP4
[0079] “Monoclonal antibody specifically directed against polyanion-modified FP4, or a fragment thereof” means an antibody or an active fragment thereof that (i) binds to polyanion-modified FP4, and does not bind, or binds insignificantly, to FP4 alone, and (ii) induces platelet activation and aggregation in the absence and / or presence of low concentrations of heparin, and whose action is inhibited in the presence of high concentrations of heparin. Preferably, such an antibody or one of its active fragments (i) binds to the FP4 / heparin complex ("FP4 / H complex"), and does not bind, or binds insignificantly, to FP4 alone, and (ii) induces platelet activation and aggregation in the absence and / or presence of low concentrations of heparin, and whose action is inhibited in the presence of high concentrations of heparin.
[0080] As will appear below in the description of the invention, the low concentrations of heparin in the presence of which such an antibody activates the platelets are generally between 0.01 and 1 IU / ml. The high concentrations in the presence of which an inhibition of the activating effect of said antibody is observed are generally between 10 and 200 IU / ml, typically of the order of 100 IU / ml.
[0081] Preferably, this antibody is a whole antibody. Preferably, this antibody is an IgG, preferably an IgG1. This antibody may be chimeric, humanized, or human. Preferably, it comprises a human Fc.
[0082] An "antibody" is a tetramer made of two heavy chains of 50-70 kDa each (called the H chains for Heavy) and two light chains of about 25 kDa each (called the L chains for Light), linked by intra- and inter-chain disulfide bonds and identical to each other. This tetramer includes at least two variable regions at the N-terminal end of each chain (called VL for the light chains and VH for the heavy chains) and a constant region at the C-terminal end, consisting of a single domain called CL for the light chain and three or four domains for the heavy chain called CH1, CH2, CH3 and possibly CH4. The region that determines the specificity of the antibody for the antigen is carried by the variable parts VH and VL, these are the parts that are responsible for recognizing the antigen. In each variable region VH and VL, three loops are brought together to form an antigen binding site.Each of the loops is called a Complementarity Determining Region (or CDR).
[0083] The assembly of the chains that make up an antibody makes it possible to define a characteristic three-dimensional Y-shaped structure, where
[0084] - the base of the Y corresponds to the Fc constant region, or Fc fragment: it is recognized by complement proteins and Fc receptors in order to mediate the effector functions of the antibody, and
[0085] - the ends of the arms of the Y correspond to the respective assembly of the variable region VL of a light chain and the variable region VH of a heavy chain, said ends constituting the Fab region and determining the specificity of the antibody for the antigen.
[0086] The Fab fragment has the same affinity for the antigen as the whole antibody. The Fab fragment is formed of the entire light chain (VL+CL) and part of the heavy chain (VH+CH1). It is monovalent.
[0087] Preferably, the monoclonal antibody (or a fragment thereof) directed specifically against polyanion-modified FP4, and preferably against the FP4 / H complex, comprises the VH and VL sequences encoded by the following nucleic acid sequences: Nucleic acid sequence encoding the VL variable region (VJ): GAAATTGTGCTCACCCAGTCTCCAACCACCATGGCTGCATCTCCCGGGGAGAAGATC ACTATCACCTGCAGTGCCAGCTCAAGTATAAGTTCCAATTACTTGCATTGGTATCAGC AGAAGCCAGGATTCTCCCCTAAACTCTTGATTTATAGGACATCCAATCTGGCTTCTGG AGTCCCAGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTCACAATTGG CACCATGGAGGCTGAAGATGTTGCCACTTACTACTGCCAGCAGGGTAGTAGTATACC GCTCACGTTCGGTGCTGGACCAAGCTGGAGCTGAAACGG (SEQ ID NO :1 )
[0088] Nucleic sequence coding for the VH variable region (VDJ):
[0089] GATGTGCAGCTTCAGGAGTCAGGACCTGACCTGGTGAAACCTTCTCAGTCACTTTCA CTCACCTGCACTGTCACTGGCTACTCCATCACCAGTGGTTATAGCTGGCACTGGATC CGGCAGTTCCAGGAAACAAACTGGAATGGATGGGCTACATACACTACAGTGGTAGC ACTAACTACAACCCATCTCTCAAAAGTCGAATCTCTATCACTCGAGACACATCCAAGA ACCAGTTCTTCCTGCAGTTGAATTCTGTGACTACTGAGGACACAGCCACATATTACTG TGCAAGAGAACTACGGCTACGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTCA CCGTCTCCTCAGCCTCC (SEQ ID NO:2)
[0090] Preferably, the monoclonal antibody (or one of its fragments) directed specifically against FP4 modified by a polyanion, and preferably against the FP4 / H complex according to the invention comprises:
[0091] - as variable region VH, the amino acid sequence encoded by SEQ ID NO: 2, and
[0092] - as variable region VL, the amino acid sequence encoded by SEQ ID NO: 1.
[0093] One such antibody is notably the 5B9 antibody, described in particular in Kizlik-Masson et al (Journal of Thrombosis and Haemostasis, 15: 2065-2075, 2017, 5B9, a monoclonal antiplatelet factor 4 / heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies).
[0094] As indicated above, such an antibody is used in the method according to the invention as an internal positive quality control, which allows a standardized expression of the results taking into account the platelet activation measured with this antibody.
[0095] Composition and preparation of the Patient Test series (TP, step 2)
[0096] The Patient Test (PT) series includes 5 mixtures, 2 of which are additional to the Validation / Standardization series: the Ago mixture and the Basal mixture.
[0097] Mixtures 2a, 2b (possibly 2b' and 2b”) and 2c are similar to mixtures 1a, 1b (possibly 1 b' and 1 b”) and 1c respectively (i.e. same quantities, same ingredients and same volumes). The 5 mixtures of the Patient Test (PT) series do not, however, include the addition of a monoclonal antibody directed specifically against polyanion-modified FP4, or one of its fragments.
[0098] The Patient Test Series assesses the ability of polyanion-modified anti-FP4 antibodies in the patient's blood to induce (i) platelet activation in the absence of heparin and / or in the presence of low heparin concentrations, and (ii) platelet inactivation in the presence of high heparin concentrations.
[0099] The presence of a platelet activator or strong agonist in the Ago mixture aims to activate the entire platelet population, and constitutes a non-specific platelet activation control allowing the threshold of positivity of the platelet activation marker to be defined.
[0100] The strong agonist is known in the state of the art. Among the various strong agonists, we can notably cite TRAP (thrombin receptor activator peptides, with 6 or 14 amino acids), calcium ionophore A23187 (chemical formula below), arachidonic acid, adenosine diphosphate (ADP), or thrombin and its derivatives. Preferably, two types of strong agonists are used depending on the final labeling of platelet activation: preferably, the strong agonist is chosen from TRAP (thrombin receptor activator peptides, with 6 or 14 amino acids) or calcium ionophore A23187, the chemical formula of which is indicated below:
[0101] [Chem 1]
[0102] The Basal mixture is a control carried out in order to have the basal level of platelet activation. The buffer of the Basal mixture is a buffer known from the prior art. Preferably, the buffer of the Basal mixture is a saline buffer such as a PBS buffer, a PBS-BSA 1% buffer, a Tyrodes HEPES-BSA 1% buffer, a PBS-BSA-NaN310X buffer, a PBS-citrate-NaN310X buffer or a PBS 10X-NaN3 buffer. These two controls (Ago and Basal) make it possible to position the positivity thresholds of the markers used to determine the level of antibody-dependent platelet activation.
[0103] Preferably, the preparation of the Patient Test series includes:
[0104] - mixing a sample of whole blood from said patient, diluted in an acceptable buffer, with the strong agonist, in order to obtain the Ago mixture;
[0105] - mixing a sample of whole blood from said patient, diluted in an acceptable buffer, with a buffer, in order to obtain a Basal mixture;
[0106] - mixing a sample of whole blood from said patient, diluted in an acceptable buffer, with FP4, in order to obtain mixture 2a;
[0107] - at least one mixture of a sample of whole blood from said patient, diluted in an acceptable buffer, with FP4 and heparin in a concentration equal to that used for mixture 1b, in order to obtain a mixture 2b. Preferably, at least two mixtures of a sample of whole blood from said patient, diluted in an acceptable buffer, with FP4 and heparin are produced, in order to obtain at least two mixtures 2b (2b' and 2b”), the heparin concentration of each mixture 2b being equal to that of each mixture 1b;
[0108] - mixing a sample of whole blood from said patient, diluted in an acceptable buffer, with FP4 and heparin in a concentration equal to that used for mixture 1c, in order to obtain a mixture 2c.
[0109] Preferably, steps 1) and 2) of the method according to the invention are carried out after 4 hours, preferably after 12 hours, preferably after 24 hours after obtaining the whole blood samples from the patient. Preferably, steps 1) and 2) of the method according to the invention are carried out at the latest 72 hours, preferably at the latest 48 hours after obtaining the whole blood samples from the patient.
[0110] The method according to the invention thus makes it possible to generate heparin-dependent platelet activation, directly evaluated in the patient's whole blood, on their own platelets. This gives the invention a considerable advantage over the tests proposed in the state of the art, since it overcomes the constraints linked to the supply of batches of platelets from healthy donors, a supply previously required by the tests prior to the invention.
[0111] Incubation and Once each series is prepared, all mixtures from steps 1) and 2) are incubated, and then the activated platelets are labeled.
[0112] Incubation is typically carried out for a period of 10 minutes to 4 hours at a temperature between 18°C and 37°C.
[0113] Preferably, the labeling of platelets is carried out using at least one marker specific for the platelet population and at least one marker specific for the activation state of the platelets. The labeling of platelets may be carried out using at least one marker specific for the platelet population and possibly two markers specific for the activation state of the platelets.
[0114] This labeling by a specific marker of the platelet activation state consists of revealing and quantifying the presence of any compound or molecule whose expression, synthesis or activation is induced when the platelets are in an activated state and whose rate of expression, synthesis or activation can make it possible to evaluate the rate of platelet activation.
[0115] Preferably the compound is selected from molecules or antigens expressed on the surface of platelets, such as P-selectin (or CD62P), phosphatidylserine (PS), LAMP-3 protein (or CD63), ADP, ATP, phosphorylated proteins or combinations thereof. Preferably, the compounds used for labeling are P-selectin (or CD62P) and phosphatidylserine (PS).
[0116] In order to identify and / or quantify this / these compound(s), antibodies or antibody fragments directed against the latter, or molecules capable of specifically recognizing the chosen compound(s) and highlighting it, are preferably used.
[0117] Typically, CD62P (or P-selectin) is a relevant candidate for assessing platelet activation. CD62P is indeed a protein contained in the alpha granules of platelets, which is expressed on the surface of platelets during platelet activation.
[0118] An anti-CD62P antibody is therefore preferentially used to mark the expression of CD62P. In addition to CD62P, or alternatively to it, the Annexin V (or AnxV) protein can also be used to highlight platelet activation. It has a strong affinity for phosphatidylserine (PS), which, initially located in the cytoplasmic layer of the resting cell, is exposed on the surface of activated platelets.
[0119] When Annexin V is used as a marker, all the mixtures used in the method according to the invention (steps 1 and 2) are made by adding a thrombin inhibitor. Such a thrombin inhibitor is preferably a direct thrombin inhibitor, preferably hirudin or argatroban. The addition of this inhibitor prevents the formation of thrombin, and secondarily of fibrin. Furthermore, when Annexin V is used as a marker, all the mixtures used in the method according to the invention (steps 1 and 2) are made by adding a calcium buffer. Indeed, the addition of a calcium buffer is essential for the exposure of phosphatidylserines and therefore for labeling by Annexin V.
[0120] In parallel, a specific labeling of the platelet population is used, targeting a compound expressed on the surface by all platelets. Such a compound is for example the CD41 marker, the CD61 marker or the combination of these markers CD41 / CD61. Preferably, an anti-CD41 antibody is used for the specific labeling of platelets in the sample.
[0121] Preferably, the markers used are coupled with fluorochromes, for example fluorescent proteins. Such fluorochromes are well known in the state of the art, and are for example allophycocyanin (APC), phycoerythrin (PE), phycoerythrin (PE)-Cy5 or Cy7, PerCP, PerCP-Cy5.5, fluorescein (FITC) or Alexa Fluor dyes.
[0122] The use of two platelet activation controls (e.g. CD62P and PS) may help optimize the performance of the method, particularly in terms of specificity and sensitivity.
[0123] Preferably, before analyzing all the mixtures, preferably on a flow cytometer, a large volume of acceptable buffer, typically between 100 μl and 5 ml, is added to each mixture. This last step makes it possible to slow down the activation of the platelets induced during steps 1 and 2, before the analysis. The buffer is preferably the same as that used specifically for the labeling of P-selectin or phosphatidylserines by Annexin V.
[0124] Analysis of mixtures incubated with markers and calculation of the platelet activation rate from the measurement of the specific labeling intensity of activated platelets in the platelet population of each mixture (steps 4 and
[0125] Once the platelet markings have been carried out, they are analyzed, preferably by flow cytometry.
[0126] Indeed, the flow cytometry technique is a particularly effective tool for assessing platelet activation in the presence of a reduced number of cellular elements. This is of major interest in this case, since the blood of patients with suspected HIT is most often thrombocytopenic.
[0127] Thus, according to this preferred embodiment, step 4) of analyzing all the mixtures obtained in step 3) comprises measuring the level of expression of CD62P and / or the exposure of phosphatidylserine on the surface of the platelets (via labeling by Annexin V) of each mixture.
[0128] Optionally, the method further comprises a step 5') of calculating the antibody-dependent platelet activation (APA) rate in each of these mixtures.
[0129] According to a preferred embodiment, the analysis of the platelets of the mixtures of each of the 2 Validation / Standardization and Patient Test series (step 4) as well as the calculation of the antibody-dependent platelet activation (APA) rate of the Ago, 2a, 2b and 2c mixtures of the TP series (step 5') are carried out according to a windowing strategy presented in the example, the description of which is given in more detail below.
[0130] Briefly, the proposed windowing strategy involves the following steps:
[0131] - a) a first sorting is carried out from the measurement of the intensity of marking of a specific compound of the platelet population to select only the platelets among the other blood elements of each mixture, on the peak of a first histogram;
[0132] - b) in the selected platelet population, the median of the labeling intensity of a compound expressed by the activated platelets (i.e. specific marker of the platelet activation state), for example CD62P and / or PS via labeling by annexin V, is measured for all the mixtures of each series on the peak of a second histogram;
[0133] - c) a threshold is determined to distinguish non-activated platelets from activated platelets on a third histogram, placed at the intersection between the peak obtained with the Ago mixture (i.e. maximum platelet activation state) in the previous step b) and the peak obtained with the Basal mixture (i.e. basal platelet activation state); and
[0134] - d) after having repositioned this threshold on the second histogram, the percentage of doubly labeled activated platelets (i.e. cellular events to the right of the threshold) is calculated for each of the mixtures of each of the 2 series.
[0135] According to a preferred method of expressing the results, in step b) the median of the total labeling intensity of the compound expressed by the activated platelets (i.e. specific marker of the activation state of the platelets) is calculated. Since the labeling is preferably carried out with fluorescent markers, the median fluorescence intensity (MFI) is therefore measured.
[0136] In this case, for each condition, the results are expressed by multiplying the percentage (%) of cells double positive for the marker of the platelet population and for the specific marker of the platelet activation state (i.e., CD41 + / CD62P +), by the total MFI of the specific marker of the platelet activation state in the platelet population (i.e., MFI of the total CD62P / CD41 + labeling) (%xMFI). These results are expressed in arbitrary units (AU).
[0137] Technical validation of the Validation / Standardization series (step 5)
[0138] Preferably, the method of the invention comprises steps 1) to 5') set out above.
[0139] According to the invention, the VS series is considered to be validated if we observe:
[0140] - activation of platelets in the sample of this series induced by an antibody or antibody fragment directed specifically against FP4 modified by a polyanion in the absence of heparin and / or in the presence of low concentrations of heparin, and
[0141] - an inhibition of this activation in the presence of high concentrations of heparin.
[0142] Preferably, step 5) consists of validating the VS series by calculating the activation ratio of this series and the inhibition ratio of this same series. Thus, according to this embodiment, two criteria are taken into account to technically validate the Validation / Standardization series:
[0143] First, in the VS series, activation should be observed with the addition of the monoclonal antibody directed specifically against polyanion-modified FP4, or one of its fragments, preferably antibody 5B9, and FP4 in the absence and / or presence of low concentrations of heparin. Thus, the VS series activation ratio is calculated between the Basal mixture in the absence of heparin and FP4, and the maximum platelet activation obtained in the presence of low concentrations of tested heparin, indicated mixtures 1b. This VS series activation ratio is calculated with the following formula: [Math 1 ]
[0144] UA max (mix 1b)
[0145] Series activation ratio VS = - — - - —
[0146] UA Basal Mix
[0147] In a second step, the heparin dependence of platelet activation induced by the monoclonal antibody directed specifically against polyanion-modified FP4, or one of its fragments, preferably antibody 5B9, is evaluated by calculating the inhibition ratio in the presence of the high concentration of heparin tested. This inhibition ratio of the VS series is calculated with the following formula:
[0148] [Math 2]
[0149] UA max (lb mix) — UA mix the
[0150] Series inhibition ratio VS = - - — — - — -
[0151] AU max (lb mix)
[0152] The Validation / Standardization series is validated only if the two previous criteria are met:
[0153] Serial activation ratio VS > threshold value, said threshold value being defined from the average obtained with sample population and by removing the outliers; and Serial inhibition ratio VS greater than or equal to a threshold value, said threshold value being between 0.3 and 0.7, preferably between 0.4 and 0.6, preferably approximately 0.5.
[0154] Preferably, the threshold for positivity of the activation ratio of the ESR series is at least 5 for the CD62P protocol and at least 4 for the Annexin V protocol. Interpretation of the results of the Patient Test series for the diagnosis of Heparin-Induced Thrombocytopenia or for a diagnosis of exclusion (steps 5' and 61
[0155] The validated results of the Validation / Standardization series allow the calculation of the antibody-dependent platelet activation rate (called APA) for the Basal, 2a, 2b and 2c mixtures of the Patient Test series (step 5'). This rate, expressed here as a percentage, is calculated from the raw results (% x MFI) expressed in AU obtained on the two series using the following formula:
[0156] [Math 3]
[0157] UA sample — UA Basal mix
[0158] APA = 100 x _ - >
[0159] AU max (lb mix) — AU Basal mix
[0160] This calculation makes it possible to overcome the variable reactivity of platelets from one patient to another and from one manipulation to another by standardizing the expression of the results obtained on the Patient Test series.
[0161] In parallel, it is also possible, if the maximum APA is higher than the defined threshold, to calculate the percentage of inhibition of the TP series according to the following formula:
[0162] [Math 4]
[0163] % inhibition series TP = 100
[0164] The activation and inhibition percentages thus calculated are compared to threshold values of positivity and inhibition established from cohorts of positive and negative control samples, these threshold values being a function of the marker considered and its expression level on the surface of the platelets.
[0165] According to the results provided by this embodiment, the invention therefore makes it possible to diagnose TlH in a patient or to exclude a diagnosis of TlH in a patient suspected of having the disease. Preferably, a diagnosis of exclusion of TlH is established when no platelet activation is observed in the presence of low heparin concentrations on the patient's TP series. Preferably, a diagnosis of TlH in a patient suspected of having the disease is confirmed when platelet activation of the patient's TP series is observed in the presence of low heparin concentrations, and inhibition of platelet activation in the presence of high heparin concentrations.
[0166] The analysis results thus obtained are interpreted as follows (step 6):
[0167] 1 / A positive diagnosis of HIT is confirmed when the two conditions below are verified for the Patient Test series:
[0168] - high platelet activation (value greater than or equal to the positivity threshold) must be observed in the presence of low heparin concentrations (mixture 2b); and
[0169] - an inhibition of this platelet activation (value greater than or equal to the inhibition threshold) must be observed in the presence of the high concentration of heparin tested (mixture 2c). This second condition makes it possible to verify the heparin dependence of the platelet activation induced by the anti-FP4 antibodies modified by a polyanion present in the patient's blood.
[0170] 11 / A diagnosis of exclusion of HIT is established in the following two cases:
[0171] • if the APA is below the positivity threshold in the presence of low heparin concentrations (mixture 2b); or
[0172] • if the APA is above the positivity threshold, but the percentage of inhibition is below the negativity threshold.
[0173] 111 / The test is considered doubtful if the APA is greater than or equal to the positivity threshold in the presence of low concentrations of heparin (mixture 2b), but the percentage of inhibition at the high concentration of heparin (mixture 2c) is in the gray zone, i.e. between the negativity threshold and the positivity threshold. In this case, the test should be repeated, preferably on a new sample.
[0174] When the method is implemented with CD62P labeling or with annexin V, the results are interpreted as follows:
[0175] For the CD62P protocol:
[0176] 1 / The test is considered positive if the APA is greater than or equal to the threshold defined in the presence of low concentrations of heparin (mixture 2b) and the percentage of inhibition in the presence of the high concentration of heparin (mixture 2c) is greater than or equal to 50%. The threshold of positivity of the APA will be defined on a population of n patients under treatment with heparin with thrombocytopenia or a drop in the platelet count greater than or equal to 40% after initiation of heparin treatment. Two different methodologies can be used:
[0177] ❖ The threshold for APA positivity can be defined using a ROC curve, favoring a specificity greater than 95%. For this, patients with a negative ELISA and a negative SRA are considered as not having the disease, while patients with a positive ELISA and a positive SRA are considered as having the disease. This methodology makes it possible to define the threshold for APA positivity max at 20% antibody-dependent platelet activation.
[0178] ❖ The threshold for APA positivity can also be defined by the mean and standard deviation of APA values measured in a population of patients with suspected HIT with a negative ELISA test and a negative SRA test.
[0179] 11 / The test is considered negative in the following two cases:
[0180] • if the APA is below the threshold defined in the presence of low heparin concentrations (mixture 2b); or
[0181] • if the APA is above the threshold defined in the presence of low concentrations of heparin (mixture 2b), but the percentage of inhibition is below the threshold of negativity.
[0182] 111 / The test is considered doubtful if the APA is greater than or equal to the threshold defined in the presence of low concentrations of heparin (mixture 2b) but the percentage of inhibition at the high concentration of heparin (mixture 2c) is between 30 and 50%. In this case, the test should be repeated preferably on a new sample.
[0183] For the Annexin V protocol:
[0184] 1 / The test is considered positive if the APA is greater than or equal to the threshold defined in the presence of low concentrations of heparin (mixture 2b) and the percentage of inhibition in the presence of the high concentration of heparin (mixture 2c) is greater than or equal to 50%.
[0185] The APA positivity threshold will be defined on a population of n patients under heparin treatment with thrombocytopenia or a drop in platelet count greater than or equal to 40% after initiation of heparin treatment. Two different methodologies can be used:
[0186] ❖ The threshold for APA positivity can be defined using a ROC curve, favoring a specificity greater than 95%. For this, patients with a negative ELISA and a negative SRA are considered as not having the disease, while patients with a positive ELISA and a positive SRA are considered as having the disease. This methodology makes it possible to define the threshold for APA positivity max at 27% antibody-dependent platelet activation.
[0187] ❖ The threshold for APA positivity can also be defined by the mean and standard deviation of APA values measured in a population of patients with suspected HIT with a negative ELISA test and a negative SRA test.
[0188] 11 / The test is considered negative in the following two cases:
[0189] • if the APA is below the threshold defined in the presence of low heparin concentrations (mixture 2b); or
[0190] • if the APA is higher than the threshold defined in the presence of low concentrations of heparin (mixture 2b) but the percentage of inhibition is lower than the threshold of negativity.
[0191] 111 / The test is considered doubtful if the APA is greater than or equal to the threshold defined in the presence of low concentrations of heparin (mixture 2b) but the percentage of inhibition at the high concentration of heparin (mixture 2c) is between 30 and 50%. In this case, the test should be repeated preferably on a new sample.
[0192] The invention is now illustrated with the following example, which example describes an embodiment of the invention by flow cytometry with the markers CD62P and Annexin V, according to a windowing strategy and a method of interpreting the results as indicated above for establishing a diagnosis of exclusion of HIT or confirmation of diagnosis of HIT.
[0193] Example: Implementation of a method according to the invention
[0194] 1 / Reagents used: [Table 1]
[0195] 2 / Description of the test (method according to the invention):
[0196] The test according to the invention is carried out with the patient's whole blood taken on sodium citrate (3.2%, 1:9, 0.109 mmol / l) and diluted in physiological serum (NaCI 9 g / l).
[0197] From the patient's blood, two series of tests are carried out: - the Validation / Standardization series is carried out after adding the chimeric monoclonal antibody 5B9, which mimics the HIT antibodies developed by the patients, to the patient's whole blood. This series allows: o on the one hand, to validate the technique by evaluating the capacity of the patient's platelets to be activated by the monoclonal antibody 5B9 in the presence of low concentrations of heparin; and o on the other hand, to standardize the expression of the results of the Patient Test series which is carried out in parallel;
[0198] - and the Patient Test series allows to evaluate the capacity of anti-FP4 / H antibodies present in the patient's blood to induce platelet activation in the presence of low and high concentrations of heparin.
[0199] For a better understanding of the examples, it is specified that in tables 2 to 14 which follow, tubes 1 and 7 of the first columns correspond respectively to mixtures 1a and 2a of the Validation / Standardization (VS) and Patient Test (TP) series, tubes 2-3 and 8-9 to mixtures 1b and 2b, tubes 4 and 10 to mixtures 1c and 2c, tube 5 to the Ago mixture and tube 6 to the Basal mixture.
[0200] 3 / Experimental procedures:
[0201] - Marking of P-selectin (CD62P) expression:
[0202] A first Validation / Standardization series is carried out with the patient's diluted blood (dilution 1 / 4) after addition of the monoclonal antibody 5B9 and incubated with exogenous platelet factor 4 (FP4) (10 pg / mL) and different concentrations of heparin (0; 0.05; 0.5 and 100 IU / ml) (ESR series, step 1).
[0203] A second series of tests (Patient Test) is carried out under the same conditions but without the addition of the 5B9 antibody (TP series, step 2). During the TP series, a non-specific platelet activation control (Ago mixture) is carried out with a strong agonist (TRAP, 50 pM). A control in the presence of PBS saline buffer (Basal mixture) is also carried out in order to have the basal level of activation of the patient's platelets. These two controls make it possible to position the positivity thresholds of the fluorescence markers used.
[0204] After incubation, labeling of activated platelets is performed using anti-CD41-APC and anti-CD62P-PE labeled antibodies (step 3). The use of anti-CD41 antibody allows specific labeling of platelets in the sample, while anti-CD62P antibody is a recognized marker for assessing platelet activation.
[0205] Both sets of tests are then analyzed by flow cytometry (step 4).
[0206] - Marking of phosphatidylserine exposure by Annexin V:
[0207] A first Validation / Standardization series is carried out with the patient's blood diluted (dilution 1 / 4) after addition of the monoclonal antibody 5B9 and incubated with exogenous platelet factor 4 (PF4) (10 pg / ml), different concentrations of heparin (0; 0.05; 0.5 and 100 IU / ml), a thrombin inhibitor (hirudin or argatroban), TRAP (100 pM) and calcium buffer (ESR series, step 1).
[0208] A second series of tests is carried out under the same conditions but in the absence of the monoclonal antibody 5B9 (TP series, step 2). A non-specific platelet activation control (Ago mixture) is carried out with a strong agonist (Calcium ionophore A23187, 5 pM). A control in the presence of PBS saline buffer (Basal mixture) is also carried out in order to have the basal level of platelet activation. These two controls make it possible to position the positivity thresholds of the fluorescence markers used.
[0209] After incubation, the labeled anti-CD41-APC antibody and Annexin V-FITC are added (step 3). Annexin V allows the exposure of phospatidylserine on the surface of activated platelets to be demonstrated.
[0210] Both sets of tests are then analyzed by flow cytometry (step 4).
[0211] An example of an experimental design carried out for the CD62P or Annexin V procedure is illustrated in Table 2:
[0212] [T able 2]
[0213] 4 / Windowing strategy (for example for CD62P marking):
[0214] First, on a first CD41-APC versus Count histogram, a threshold is positioned to distinguish platelets (CD41+) from other blood cells that do not express this marker (CD41-):
[0215] ■=> Platelet analysis
[0216] Then, among all CD41+ cells, the total median fluorescence intensity (MFI) of the CD62P marker is measured on a second histogram:
[0217] ■=> Measurement of the MFI of CD41 + / CD62P cells
[0218] The threshold for distinguishing CD41 + / CD62P- cells (non-activated platelets) from CD41 + / CD62P+ double-positive cells (activated platelets) is positioned at the intersection of the two peaks between the TRAP-activated condition (tube 5) and the resting condition (tube 6) on the third CD62P-PE versus Count histogram. After repositioning this threshold on the second histogram, the percentage of CD41 + / CD62P+ double-positive cells is calculated for each condition tested:
[0219] ■=> Measurement of the percentage of double positive CD41 + / CD62P + cells.
[0220] 5 / Expressions of the results:
[0221] According to one of the methods of calculating and expressing the results as proposed in the description above, it is recalled that: a / For each of the conditions, the results are expressed by multiplying the percentage of activated CD41 + / CD62+ cells by their MFI (MFI CD62P). This product is noted "% x MFI" and expressed in arbitrary unit (LIA); b / In order to overcome variable reactivity of platelets from one patient to another and from one manipulation to another, the raw results (% x MFI) obtained on the Validation / Standardization series make it possible to standardize the expression of the results obtained on the Patient Test series by performing the following calculation for each tube:
[0222] [Math 3]
[0223] UA sample — UA Basal mix
[0224] AP A = 100 x _ - _
[0225] UA max (mixture 1b) — UA Basal mix c / The percentage of inhibition of the TP series is also calculated with the formula:
[0226] [Math 4]
[0227] % inhibition series TP = 100
[0228] 6 / Example of results obtained in two patients with suspected HIT:
[0229] Any slight differences that may be noted between the following tables and the calculations given by the formulas above are inherent to the device used, which makes automatic adjustments to the values. a / Results obtained with the CD62P marking:
[0230] The results obtained for the CD62P marker of patient 1 are as follows:
[0231] [Table 3] The results obtained for the CD62P marker of patient 2 are as follows:
[0232] [Table 4] b / Results obtained with the Annexin marker (AnxV): With Annexin V labeling, a windowing strategy and expression of results similar to that presented for the CD62P protocol are applied.
[0233] The results obtained for the Annexin V marker of patient 1 are as follows:
[0234] [T able 5]
[0235] The results obtained for the Annexin V marker of patient 2 are as follows: [T able 6] c / Interpretation of CD62P and Annexin results;
[0236] For these 2 patients, the Validation / Standardization (VS) series objective an increase in the parameter “% x MFI” expressed in UA in the presence of FP4 and low concentrations of heparin (0.05 and / or 0.5 IU / rnl, tubes 2 and 3 respectively (mixtures 1 b)) compared to the basal condition (PBS, tube 6, Basal mix), with an inhibition of platelet activation in the presence of 100 IU / rnl of heparin (tube 4, mix 1c) for the 2 markers studied.
[0237] For P-selectin (CD62P) labeling, a VS series activation ratio of 299.8 and 13.2, respectively for patients 1 and 2, highlights platelet activation in the presence of low heparin concentrations (positivity threshold 5).
[0238] For these 2 patients, a VS series inhibition ratio equal to 0.88 and 0.9, respectively, is obtained demonstrating an inhibition of the activation induced by the 5B9 antibody in the presence of the high concentration of heparin (threshold > 0.5).
[0239] For the labeling of the exposure of phosphatidylserines by Annexin V, an activation ratio of the VS series of 95.9 and 11.3, respectively for patients 1 and 2 highlights a platelet activation in the presence of low concentrations of heparin (positivity threshold 4). For these 2 patients an inhibition ratio of the VS series equal to 0.85 and 0.65, respectively is obtained demonstrating an inhibition of the activation induced by the 5B9 antibody in the presence of the high concentration of heparin (threshold > 0.5). These results obtained with the VS series in the presence of the monoclonal antibody 5B9 demonstrate that the method according to the invention makes it possible to highlight a platelet activation induced by the presence of anti-FP4 antibodies modified by an activating polyanion in the blood of the patient tested and makes it possible to interpret the results of the TP series.
[0240] For the CD62P expression labeling of patient 1's TP series, the maximum rate of antibody-dependent platelet activation (APA) calculated in the presence of low concentrations of heparin (0.05 and / or 0.5 IU / ml, mixtures 2b) (according to the formula described in Math 3 above) is equal to 28% (positive threshold > 20%), with an inhibition of 94% (threshold > 50%) in the presence of the high concentration of heparin tested (100 IU / ml, mixture 2c). For this parameter, the TP series is positive showing heparin-dependent platelet activation.
[0241] On the other hand, for patient 2, no platelet activation is observed, presence of low concentrations of heparin (0.05 and / or 0.5 IU / ml, mixtures 2b): maximum APA at 1% therefore lower than the test positivity threshold. For this parameter, the TP series is negative. The result of this functional test is unfavorable to the diagnosis of HIT.
[0242] For the labeling of phosphatidylserine exposure by Annexin V of the TP series of patient 1, the calculated percentage of antibody-dependent platelet activation is equal to 215% (positive threshold > 27%), with an inhibition of 96% (threshold > 50%) in the presence of the high concentration of heparin tested (100 IU / ml, mixture 2c). For this parameter, the TP series is positive. The result of this functional test is in favor of the diagnosis of HIT.
[0243] On the other hand, for patient 2, no platelet activation is observed in the presence of low heparin concentrations (0.05 and / or 0.5 IU / ml, mixtures 2b): maximum APA at 16%, therefore lower than the test's positivity threshold. For this parameter, the TP series is negative. The result of this functional test is unfavorable to the diagnosis of HIT.
[0244] These results (patients 1 and 2) were confirmed with the reference platelet activation test for the diagnosis of HIT: the serotonin release assay (S RA).
[0245] As a reminder, the SRA is a functional test for the diagnosis of HIT. This test is based on the measurement of the release, during platelet activation, of radiolabeled serotonin ( 14C- serotonin), previously incorporated into the dense granules. The platelet washing steps allow the elimination of the plasma matrix. The addition of different concentrations of heparin allows the formation of FP4 / H complexes on the surface of the platelets of the healthy donor. The pathogenic antibodies recognize, by their Fab fragment, the macromolecular FP4 / H complexes and activate the platelets via their Fc fragment which binds to the FcyllA receptor. The contents of the granules are released into the reaction medium and the radioactivity measured in the supernatant is directly proportional to the platelet activation.
[0246] 7 / Example of results obtained in four patients (patients 3 to 6) with suspected HIT:
[0247] Any slight differences that may be noted between the following tables and the calculations given by the formulas above are inherent to the device used, which makes automatic adjustments to the values. a / Results obtained with the CD62P marking:
[0248] The results obtained for the CD62P marker of patient 3 are as follows: [T able 7]
[0249] The results obtained for the CD62P marker of patient 4 are as follows: [T able 8]
[0250] The results obtained for the CD62P marker of patient 5 are as follows: [Table 9] b / Results obtained with the Annexin marker;
[0251] The results obtained for the marker by the AnxV of patient 3 are as follows: [T able 11]
[0252] The results obtained for the marker by the AnxV of patient 4 are as follows:
[0253] [Table 12]
[0254] The results obtained for the marker by the AnxV of patient 5 are as follows: [Table 13] The results obtained for the marker by the AnxV of patient 6 are as follows:
[0255] [Table 14] c / Interpretation of CD62P and Annexin V results;
[0256] For patients 3 to 6, the VS series demonstrate:
[0257] - an increase in the parameter “% x MFI” expressed in LIA in the presence of FP4 and in the presence of low concentrations of heparin (0.05 and / or 0.5 IU / ml, tubes 2 and / or 3 respectively, mixtures 1 b) compared to the basal condition (PBS, tube 6, Basal mixture) thanks to the activation ratio of the VS series higher than the threshold,
[0258] - and an inhibition of platelet activation in the presence of 100 IU / rnl of heparin (tube 4, mixture 1c) for the 2 markers studied with the inhibition ratio of the VS series above the threshold. This inhibition of platelet activation in the presence of a high concentration of heparin is characteristic of Tl H antibodies.
[0259] These results obtained with the VS series in the presence of the monoclonal antibody 5B9 demonstrate that the method according to the invention makes it possible to highlight platelet activation induced by the presence of activating anti-FP4 / H antibodies in the blood of the patient tested.
[0260] Concerning the results obtained for the TP series with the blood of patients 3 and 5, an increase in APA is observed, in the presence of low concentrations of heparin (0.05 and / or 0.5 IU / ml, tube(s) 8 and / or 9 respectively, i.e. mixture(s) 2b) compared to the basal condition (tube 6, PBS, Basal mixture). The inhibition of platelet activation in the presence of 100 IU / ml of heparin (tube 10, mixture 2c) is observed for the 2 markers studied. These results demonstrate the presence of activating (pathogenic) and heparin-dependent anti-FP4 antibodies in this sample. The results obtained for patients 3 and 5 are in favor of the diagnosis of HIT. The results of the biological tests must be compared with the clinical data in order to confirm or exclude the diagnosis of Heparin-Induced Thrombocytopenia.In contrast, for patients 4 and 6, no platelet activation was observed, regardless of the marker used, which demonstrates the absence of activating (pathogenic) antibodies in the blood of these patients. The results obtained for patients 4 and 6 are in disfavor of the diagnosis of HIT.
[0261] These results (patients 3 to 6) were confirmed with the reference test (SRA, Serotonin Release Assay).
Claims
DEMANDS 1. Method for analyzing heparin-dependent platelet activation in a patient suspected of having thrombocytopenia induced by anti-platelet factor 4 (PF4) antibodies modified by a polyanion, comprising the following steps: 1) the preparation of a series of tests necessary for validation and standardization, hereinafter referred to as the Validation / Standardization (VS) series, said Validation / Standardization series comprising: - the mixing of a whole blood sample of said patient, diluted in an acceptable buffer, in the presence of exogenous platelet factor (PF4), and a monoclonal antibody directed specifically against platelet factor 4 modified by a polyanion, preferably by heparin, or one of its fragments in order to obtain a mixture 1a; - at least one mixture of a whole blood sample of said patient, diluted in an acceptable buffer, with exogenous FP4, a monoclonal antibody specifically directed against polyanion-modified FP4, or one of its fragments, and heparin at a concentration between 0.01 and 1 IU / mL, in order to obtain at least one mixture 1b; - at least one mixture of a whole blood sample of said patient, diluted in an acceptable buffer, with exogenous FP4, a monoclonal antibody specifically directed against polyanion-modified FP4, or one of its fragments, and heparin at a concentration between 10 and 200 IU / ml, in order to obtain at least one 1c mixture; 2) the preparation of a Patient Test Series (PT), said Patient Test Series comprising: - the mixing of a whole blood sample from said patient, diluted in an acceptable buffer, with a platelet activator or a strong agonist, in order to obtain an Ago mixture; - the mixing of a sample of whole blood from said patient, diluted in an acceptable buffer, in order to obtain the Basal mixture; - the mixing of a whole blood sample of said patient, diluted in an acceptable buffer, with FP4, in order to obtain a mixture 2a; - at least one mixture of a whole blood sample of said patient, diluted in an acceptable buffer, with FP4 and heparin at a concentration equal to that used for mixture 1b, in order to obtain mixture 2b; - at least one mixture of a whole blood sample of said patient, diluted in an acceptable buffer, with FP4 and heparin at a concentration equal to that used for mixture 1c, in order to obtain a mixture 2c; 3) Incubation of all mixtures from the VS and TP series, followed by labeling of the platelet population and specific labeling of activated platelets in this population in each mixture; and 4) the analysis of all the mixtures obtained in step 3).
2. Analytical method according to claim 1, wherein the patient is suspected of having thrombocytopenia induced by antibodies directed against heparin-modified FP4 factor.
3. Method according to claim 1 or 2 comprising the preparation of at least two mixtures 1b in step 1), preferably two mixtures 1b (i.e. mixtures 1b' and 1b”) are made, on the one hand, with a heparin concentration of between 0.01 and 0.1 IU / mL, preferably between 0.02 and 0.08 IU / mL, for the first mixture 1b', and on the other hand, between 0.2 and 1 IU / mL, preferably between 0.3 and 0.8 IU / mL for the second mixture 1b”.
4. Method according to any one of claims 1 to 3, comprising, following the step 4), the additional step 5) of validation of the VS series by calculating the activation ratio of this series and the calculation of the inhibition ratio of this same series.
5. Method according to claim 4, wherein the VS series is validated if the following is observed: - activation of platelets in the sample from this series induced by an antibody or antibody fragment specifically directed against polyanion-modified FP4, in the absence of heparin and / or in the presence of low heparin concentrations, and - an inhibition of this activation in the presence of high concentrations of heparin.
6. Method according to any one of claims 1 to 5, which is a flow cytometry analysis method.
7. Method according to any one of claims 4 to 6, comprising, following the step 5), a step 5') of calculating the antibody-dependent platelet activation rate (named APA) of the Ago, 2a, 2b and 2c mixtures of the TP series.
8. A method according to any one of the preceding claims, wherein all the patient's whole blood samples used are diluted to 1 / 10th, preferably diluted in a proportion of 1 / 2 to 1 / 10 ème , and preferably a quarter of it, in physiological saline.
9. A method according to any one of the preceding claims, wherein the monoclonal antibody specifically directed against polyanion-modified FP4 comprises: - as the variable region VH, the amino acid sequence encoded by SEQ ID NO:2, and - as variable region VL, the amino acid sequence encoded by SEQ ID NO:
1.
10. Method according to any one of the preceding claims, wherein the platelet labeling of step 3) is carried out using at least one platelet population-specific marker and at least one platelet activation-state-specific marker, preferably using at least one platelet population-specific marker and possibly two platelet activation-state-specific markers.
11. Method according to claim 10, wherein the platelet labeling of step 3) is carried out using at least one platelet population-specific marker selected from the CD41 marker, the CD61 marker and the combination of these CD41 / CD61 markers, and at least one platelet activation state-specific marker, preferably two, selected from P-selectin and phosphatidylserine.
12. Method for excluding heparin-induced thrombocytopenia (HIT) in a patient, comprising the method according to any one of claims 7 to 11, and a step 6) of interpreting antibody-dependent platelet activation (APA) levels calculated in each mixture of the TP series for establishing a diagnosis of HIT exclusion.
13. Method according to claim 12, characterized in that a diagnosis of exclusion of HIT is established when no platelet activation is observed in the presence of low concentrations of heparin on the patient's PT series.
14. Method for confirming a diagnosis of HIT in a patient suspected of having the disease, comprising the method according to any one of claims 7 to 11, as well as a step 6) of interpreting antibody-dependent platelet activation rates (APA) calculated in each mixture of the TP series for the establishment of a diagnosis of HIT.
15. Method according to claim 14, characterized in that a diagnosis of HIT in a patient suspected of having the disease is confirmed when platelet activation of the patient's TP series is observed in the presence of low concentrations of heparin, and inhibition of platelet activation is observed in the presence of high concentrations of heparin.
